The financials
GeneDx Holdings Corp. by the numbers
GeneDx Holdings Corp. (WGS) reported revenue of $102M in Q1 2026 (quarter ended Mar 31, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 67% and net loss of $63M. For the full year FY2025, revenue was $428M (+40% year on year) and net income −$21M. Its largest product in Jun 2026 was Diagnostic Test Third Party Insurance at $95M, 83% of the disclosed total, well ahead of Diagnostic Test Institutional Customers at 14%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $102M | $87M | +17% |
| Gross profit | $68M | $58M | +17% |
| Operating income | −$57M | −$4.6M | n/a |
| Net income | −$63M | −$6.5M | n/a |
| Diluted EPS | −$2.16 | −$0.23 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Diagnostic Test Third Party Insurance | $95M | 83% |
| Diagnostic Test Institutional Customers | $16M | 14% |
| Product And Service Other | $2.6M | 2.2% |
| Diagnostic Test Self Pay | $1.0M | 0.9% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $114.4M (+13%)
Diagnostic Test Self Pay grew +207% year on yearDiagnostic Test Institutional Customers -14% year on year
Segment Latestquarter on quarteryear on year
- Diagnostic Test Third Party Insurance$94.7M$94.7MQoQ +12%year on year +17%+12%+17%
- Diagnostic Test Institutional Customers$16.1M$16.1MQoQ +3.8%year on year -14%+3.8%-14%
- Product And Service Other$2.6M$2.6MQoQ +167%year on year -1.5%+167%-1.5%
- Diagnostic Test Self Pay$1.0M$1.0MQoQ +264%year on year +207%+264%+207%
Diagnostics & Research
Ranks #15 of 17 by Smart Score